Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of CVL006 combination therapy in advanced solid tumors
CTR20253553Phase 2Active
- Sponsor
- Convalife Pharmaceutical
- Start
- Sep 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of CVL006 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), pleural mesothelioma and 5 more (13 arms), sponsored by Convalife Pharmaceutical. Primary endpoints: Dose-limiting toxicity and recommended phase II dose, Progression-free survival and 1 more. Started Sep 2025; status: active.
02
Drugs
CVL006
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)pleural mesotheliomatriple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on CTR20253553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253553.